| Younger | Older | Sarcopenic |
---|---|---|---|
 | (n = 40) | (n = 40) | (n = 40) |
Women | |||
 Biochemical variables | |||
  Myostatin (ng/mL) | 5.5 (3.2–7.3) | 7.3 (5.7–11.7)* | 5.3 (4.2–8.0)*** |
  Myostatin/TBLM (ng/ml/kg) | 0.142 (0.091–0.195) | 0.199 (0.138–0.327)* | 0.175 (0.145–0.255)** |
  Propeptide (ng/ml) | 7.1 (5.2–10.8) | 11.4 (7.3–20.1)* | 10.0 (6.5–12.4)*** |
  Propeptide/TBLM (ng/ml/kg) | 0.194 (0.139–0.294) | 0.292 (0.186–0.203)* | 0.307 (0.203–0.417)** |
  FLRG (ng/mL) | 5.1 (4.3–6.0) | 7.3 (6.2–9.7)* | 8.3 (6.7–10.6)** |
  GASP1 (ng/mL) | 7.6 (6.5–10.1) | 9.4 (7.2–11.0) | 9.2 (7.1–12.2)** |
  Total 25-(OH)D (ng/mL) | 25.0 (17.3–34.8) | 20.0 (14.3–24.0)* | 18.5 (14.0–24.8)** |
  IGF-1 (ng/mL) | 235 (191–305) | 141 (93–183)* | 105 (78–147)**,*** |
  IGF-2 (ng/mL) | 1160 (958–1375) | 1112 (933–1367) | 1167 (884–1336) |
  IGFBP-2 (ng/mL) | 406 (190–621) | 447 (308–775) | 635 (539–987)**,*** |
  IGFBP-3 (ng/mL) | 4580 (4099–5094) | 4096 (3536–4513)* | 3913 (3171–4389)** |
  Total E1 (pg/mL) | 47.0 (33.3–57.8) | 31.0 (19.0–37.0)* | 23.0 (16.0–29.0)** |
  Total E2 (pg/mL) | 54.0 (30.5–108.5) | 5.6 (4.2–9.1)* | 4.9 (3.2–7.3)** |
  Total T (ng/dL) | 23.5 (18.0–30.0) | 16.0 (12.0–24.0)* | 21.0 (11.0–30.0) |
  Bio E2 (pg/mL) | 15.0 (8.2–28.2) | 2.1 (1.0–3.2)* | 1.0 (0.6–1.7)**,*** |
  Bio T (ng/dL) | 1.5 (0.9–2.1) | 1.5 (1.0–2.6) | 1.1 (0.7–1.8)*** |
  SHBG (nmol/L) | 63.1 (45.0–95.6) | 40.5 (23.2–57.8)* | 52.8 (46.7–73.0)*** |
Men | |||
 Biochemical variables | |||
  Myostatin (ng/mL) | 10.5 (9.0–14.4) | 7.1 (5.4–8.8)* | 6.9 (4.4–8.9)** |
  Myostatin/TBLM (ng/ml/kg) | 0.192 (0.156–0.241) | 0.131 (0.101–0.164)* | 0.153 (0.092–0.192)** |
  Propeptide (ng/ml) | 15.7 (11.7–19.4) | 11.8 (7.6–15.7) | 10.8 (6.4–14.9)** |
  Propeptide/TBLM (ng/ml/kg) | 0.276 (0.207–0.328) | 0.216 (0.137–0.305) | 0.240 (0.153–0.309) |
  FLRG (ng/mL) | 4.5 (3.8–5.3) | 7.5 (6.1–9.4)* | 7.4 (6.3–9.9)** |
  GASP1 (ng/mL) | 9.4 (7.5–10.6) | 9.4 (7.3–10.7) | 10.3 (8.9–11.9) |
  Total 25-(OH)D (ng/mL) | 23.5 (17.0–31.8) | 21.5 (17.0–25.8) | 21.0 (16.0–26.8) |
  IGF-1 (ng/mL) | 344 (292–446) | 193 (114–245)* | 169 (103–245)** |
  IGF-2 (ng/mL) | 1099 (1005–1226) | 961 (774–1075)* | 964 (785–1071)** |
  IGFBP-2 (ng/mL) | 244 (142–361) | 547 (391–728)* | 758 (531–1049)** |
  IGFBP-3 (ng/mL) | 4469 (3833–4988) | 3202 (2596–3581)* | 3230 (2613–4019)**,*** |
  Total E1 (pg/mL) | 32.5 (25.3–38.0) | 35.0 (30.0–45.0)* | 31.0 (25.5–44.0) |
  Total E2 (pg/mL) | 23.0 (19.0–30.0) | 25.0 (20.0–28.0) | 23.0 (18.0–29.0) |
  Total T (ng/dL) | 462 (392–549) | 424 (321–526) | 484 (388–609) |
  Bio E2 (pg/mL) | 12.8 (11.0–17.5) | 9.5 (7.1–11.0)* | 7.4 (5.5–10.0)** |
  Bio T (ng/dL) | 133 (115–156) | 50.8 (37.0–63.5)* | 50.8 (37.4–62.7)** |
  SHBG (nmol/L) | 25.1 (19.4–31.3) | 45.5 (39.0–58.6)* | 50.3 (39.9–64.0)** |